AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02266524
Drug: Tamsulosin hydrochloride, medium dose
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02266524
Drug: Tamsulosin hydrochloride, high dose
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00692978
Drug: Fluticasone Propionate_1.5
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
Trial: NCT01704261
Drug: Omarigliptin
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 25 mg capsule administered orally once a week
Trial: NCT01704261
Drug: Matching placebo to Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Matching placebo to omarigliptin capsule administered orally once a week
Trial: NCT00692978
Drug: Fluticasone Propionate_3
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
Trial: NCT00692978
Drug: Fluticasone Propionate_6
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
Trial: NCT00692978
Drug: FP From Active 250 ug MDI Inhaler
RxNorm normalized name: activated charcoal 250 MG
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
Trial: NCT01704261
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
Trial: NCT01704261
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
Trial: NCT03796351
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.
Trial: NCT00329485
Drug: CORvalen (D-Ribose)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00584597
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Control
Trial: NCT03337503
Drug: High CBD with trace THC oil
RxNorm normalized name: Mineral Oil (high Viscosity)
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule containing cannabis oil
Trial: NCT00421421
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02985697
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention being tested is intranasal dexmedetomidine
Trial: NCT02985697
Drug: Midazolam Hydrochloride
RxNorm normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
Trial: NCT02985697
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.
Trial: NCT01565538
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg Given orally
Trial: NCT01565538
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg/m2 Given IV
Trial: NCT00690456
Drug: Rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT00690456
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin continued at stable dose as background therapy
Trial: NCT01012739
Drug: Indacaterol 150 μg via the Concept1 dry-powder inhaler
RxNorm normalized name: Indacaterol Inhalation Powder
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Trial: NCT00515086
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets taken once a day with a full glass of water.
Trial: NCT01012739
Drug: Indacaterol 60 μg via the Simoon dry-powder inhaler
RxNorm normalized name: budesonide
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Trial: NCT01012739
Drug: Indacaterol 120 μg via the Simoon dry-powder inhaler
RxNorm normalized name: budesonide
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Trial: NCT01012739
Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler
RxNorm normalized name: Indacaterol Inhalation Powder
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Trial: NCT04897243
Drug: Biktarvy
RxNorm normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
Trial: NCT00274989
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6
Trial: NCT01021332
Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01021332
Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03449472
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription quetiapine medication
Trial: NCT01503788
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
Trial: NCT00310544
Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
Trial: NCT00310544
Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
Trial: NCT03387917
Drug: TLD-1
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
Trial: NCT03387917
Drug: Caelyx
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caelyx is a liposomal formulation of the anthracycline doxorubicin
Trial: NCT05840445
Drug: Onabotulinum toxin A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular application of onabotulinum toxin-A in the upper facial third.
Trial: NCT05840445
Drug: Prabotulinumtoxin A
RxNorm normalized name: Prabotulinumtoxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular application of prabotulinum toxin-A in the upper facial third.
Trial: NCT00317096
Drug: rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 courses of rituximab maintenance after completion of salvage therapy
Trial: NCT00051896
Drug: GBR 12909
RxNorm normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01576315
Drug: Itraconazole/voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
Trial: NCT00831597
Drug: bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 120 mg/m2 IV, Days 1, 2 of Cycles 1-6
Trial: NCT00831597
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 IV, Day 1 of Cycles 1-6
Trial: NCT01002274
Drug: MCS-2
RxNorm normalized name: MC-3
DrugBank: TMC-310911 (DB15623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 soft-gel capsules Qd for 40 weeks
Trial: NCT03790397
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients treated with Osimertinib within the Special Use medication Program (SUMP).
Trial: NCT01598025
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01598025
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01598025
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01501929
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Trial: NCT01501929
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Trial: NCT00166530
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg atorvastatin once daily for 12 weeks. Tablets
Trial: NCT02545244
Drug: 0.12% Chlorhexidine Mouthwash.
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
Trial: NCT03312426
Drug: BMS-986205
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose, 100 mg administered at Day 1 and at Day 15.
Trial: NCT01112748
Drug: Topical lidocaine patch
RxNorm normalized name: lidocaine Medicated Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
Trial: NCT04398953
Drug: TQ-B3525
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Trial: NCT00081809
Drug: autologous human tumor-derived HSPPC-96
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03425292
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: concomitant and 5-day adjuvant temozolomide
Trial: NCT03425292
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
Trial: NCT03425292
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
Trial: NCT02846701
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
Trial: NCT03425292
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
Trial: NCT03425292
Drug: 5-day Temozolomide
RxNorm normalized name: temozolomide 5 MG
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)
Trial: NCT03425292
Drug: 5-day Temozolomide
RxNorm normalized name: temozolomide 5 MG
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)
Trial: NCT03425292
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m\^2 oral, on Day 1 of each 6 week course
Trial: NCT03425292
Drug: Nivolumab monotherapy
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
Trial: NCT00106431
Drug: romidepsin (depsipeptide, FK228)
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
Trial: NCT04447729
Drug: fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two doses, each dose consists of 4 injections with prefilled syringes
Trial: NCT03323801
Drug: 13-cis retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accutane is used for the treatment of severe acne
Trial: NCT00471640
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 days 5 mg
Trial: NCT05748054
Drug: Silver Diamine Fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
Trial: NCT02398838
Drug: Home administration of 200 mg mifepristone
RxNorm normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home administration of 200 mg mifepristone.
Trial: NCT02398838
Drug: Home or clinic administration of 400 mcg buccal misoprostol
RxNorm normalized name: misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home or clinic administration of 400 mcg buccal misoprostol
Trial: NCT02873338
Drug: Dociparstat sodium
RxNorm normalized name: Dociparstat sodium
DrugBank: Dociparstat sodium (DB16481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
Trial: NCT02873338
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
Trial: NCT02873338
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
Trial: NCT02673749
Drug: RP-G28
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug taken orally
Trial: NCT03931070
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
Trial: NCT02913417
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 1mg/kg every 3 weeks x 4
Trial: NCT02913417
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
Trial: NCT02707497
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
Trial: NCT00622388
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
Trial: NCT02180022
Drug: Onion peel extract
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, onion peel extract was treated for 12 weeks
Trial: NCT00425503
Drug: PS-341 (bortezomib)
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
Trial: NCT04225221
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
Trial: NCT04225221
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
Trial: NCT01795027
Drug: S-1 plus oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
Trial: NCT00486460
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00486460
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no